GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer
Background: Immune infiltration of the tumor microenvironment offers unlimited possibilities for therapeutic strategies in cervical cancer, where GRAP2 is an adaptor protein engaged in diverse signal activations. However, uncertainty exists regarding GRAP2’s prognostic significance and its relations...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-03-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/50/3/10.31083/j.ceog5003057 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850260231317094400 |
|---|---|
| author | Shixin Lin Jun Zhu Xiaoling Mao Gang Lin Dan Yang Yun Guan Jun Gao |
| author_facet | Shixin Lin Jun Zhu Xiaoling Mao Gang Lin Dan Yang Yun Guan Jun Gao |
| author_sort | Shixin Lin |
| collection | DOAJ |
| description | Background: Immune infiltration of the tumor microenvironment offers unlimited possibilities for therapeutic strategies in cervical cancer, where GRAP2 is an adaptor protein engaged in diverse signal activations. However, uncertainty exists regarding GRAP2’s prognostic significance and its relationship to immune infiltration. Methods: The data on cervical cancer cases were downloaded from The Cancer Genome Atlas (TCGA) database. The ESTIMATE computational technique was utilized to calculate the amount of immunological and stromal components, which helped us to identify the differential expression genes (DEGs). Among them, GRAP2 was considered to be related to overall survival based on a protein-protein interaction network and a univariate Cox regression analysis. Thus, based on the Gene Expression Omnibus (GEO) and TCGA databases, we evaluated GRAP2’s influence on clinical prognosis. Furthermore, GRAP2 expression was analyzed by Gene Set Enrichment Analysis (GSEA). Finally, we used CIBERSORTx analysis to assess the proportion of tumor-infiltrating immune cells (TICs) and the connection between GRAP2 and the tumor immune microenvironment. Results: ESTIMATEScore was associated with cervical cancer patient’s prognosis. There are 791 DEGs and 11 potential key genes were identified including GRAP2. In survival analyses with clinical information, We found that the GRAP2 high expression group exhibited a significantly longer overall survival (OS) than the low expression group and that the gene expression gradually declined as the Federation of International of Gynecologists and Obstetricians (FIGO) stage and M classification increased. GRAP2 was strongly linked with immunity and metabolism, according to GSEA. Finally, we discovered that 11 different TIC types and GRAP2 expressions were linked. Conclusions: GRAP2 may be a novel immune-related prognosis biomarker in cervical cancer. |
| format | Article |
| id | doaj-art-ee6caede510440838c34dbb3da042f59 |
| institution | OA Journals |
| issn | 0390-6663 |
| language | English |
| publishDate | 2023-03-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj-art-ee6caede510440838c34dbb3da042f592025-08-20T01:55:41ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632023-03-015035710.31083/j.ceog5003057S0390-6663(23)02006-7GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical CancerShixin Lin0Jun Zhu1Xiaoling Mao2Gang Lin3Dan Yang4Yun Guan5Jun Gao6Department of Third Clinical Medical College of Nanchang University, The First Hospital of Nanchang, 330008 Nanchang, Jiangxi, ChinaDepartment of Third Clinical Medical College of Nanchang University, The First Hospital of Nanchang, 330008 Nanchang, Jiangxi, ChinaDepartment of Nanchang Key Laboratory for Precision Therapy of Gynecological Tumor, The First Hospital of Nanchang, 330008 Nanchang, Jiangxi, ChinaDepartment of Nanchang Key Laboratory for Precision Therapy of Gynecological Tumor, The First Hospital of Nanchang, 330008 Nanchang, Jiangxi, ChinaDepartment of Third Clinical Medical College of Nanchang University, The First Hospital of Nanchang, 330008 Nanchang, Jiangxi, ChinaDepartment of Third Clinical Medical College of Nanchang University, The First Hospital of Nanchang, 330008 Nanchang, Jiangxi, ChinaDepartment of Gynecologic Oncology, Jiangxi Cancer Hospital, 330029 Nanchang, Jiangxi, ChinaBackground: Immune infiltration of the tumor microenvironment offers unlimited possibilities for therapeutic strategies in cervical cancer, where GRAP2 is an adaptor protein engaged in diverse signal activations. However, uncertainty exists regarding GRAP2’s prognostic significance and its relationship to immune infiltration. Methods: The data on cervical cancer cases were downloaded from The Cancer Genome Atlas (TCGA) database. The ESTIMATE computational technique was utilized to calculate the amount of immunological and stromal components, which helped us to identify the differential expression genes (DEGs). Among them, GRAP2 was considered to be related to overall survival based on a protein-protein interaction network and a univariate Cox regression analysis. Thus, based on the Gene Expression Omnibus (GEO) and TCGA databases, we evaluated GRAP2’s influence on clinical prognosis. Furthermore, GRAP2 expression was analyzed by Gene Set Enrichment Analysis (GSEA). Finally, we used CIBERSORTx analysis to assess the proportion of tumor-infiltrating immune cells (TICs) and the connection between GRAP2 and the tumor immune microenvironment. Results: ESTIMATEScore was associated with cervical cancer patient’s prognosis. There are 791 DEGs and 11 potential key genes were identified including GRAP2. In survival analyses with clinical information, We found that the GRAP2 high expression group exhibited a significantly longer overall survival (OS) than the low expression group and that the gene expression gradually declined as the Federation of International of Gynecologists and Obstetricians (FIGO) stage and M classification increased. GRAP2 was strongly linked with immunity and metabolism, according to GSEA. Finally, we discovered that 11 different TIC types and GRAP2 expressions were linked. Conclusions: GRAP2 may be a novel immune-related prognosis biomarker in cervical cancer.https://www.imrpress.com/journal/CEOG/50/3/10.31083/j.ceog5003057cervical cancergrap2tumor microenvironmentimmunotherapyprognostic biomarker |
| spellingShingle | Shixin Lin Jun Zhu Xiaoling Mao Gang Lin Dan Yang Yun Guan Jun Gao GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer Clinical and Experimental Obstetrics & Gynecology cervical cancer grap2 tumor microenvironment immunotherapy prognostic biomarker |
| title | GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer |
| title_full | GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer |
| title_fullStr | GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer |
| title_full_unstemmed | GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer |
| title_short | GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer |
| title_sort | grap2 a novel immune related prognosis biomarker in cervical cancer |
| topic | cervical cancer grap2 tumor microenvironment immunotherapy prognostic biomarker |
| url | https://www.imrpress.com/journal/CEOG/50/3/10.31083/j.ceog5003057 |
| work_keys_str_mv | AT shixinlin grap2anovelimmunerelatedprognosisbiomarkerincervicalcancer AT junzhu grap2anovelimmunerelatedprognosisbiomarkerincervicalcancer AT xiaolingmao grap2anovelimmunerelatedprognosisbiomarkerincervicalcancer AT ganglin grap2anovelimmunerelatedprognosisbiomarkerincervicalcancer AT danyang grap2anovelimmunerelatedprognosisbiomarkerincervicalcancer AT yunguan grap2anovelimmunerelatedprognosisbiomarkerincervicalcancer AT jungao grap2anovelimmunerelatedprognosisbiomarkerincervicalcancer |